<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01847131</url>
  </required_header>
  <id_info>
    <org_study_id>R015532021</org_study_id>
    <nct_id>NCT01847131</nct_id>
  </id_info>
  <brief_title>Effectiveness of Oxymetazoline Added on Nasal Steroid in Rhinitis With Persistent Nasal Obstruction</brief_title>
  <official_title>Effectiveness of Oxymetazoline Added on Intranasal Steroid in the Treatment of Allergic and Nonallergic Rhinitis With Persistent Nasal Obstruction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mahidol University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mahidol University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background Allergic rhinitis is a common health problem with a worldwide prevalence is
      10-25%, and poses significant impact on the quality of life of the patients. In Thailand, the
      prevalence of allergic rhinitis in the general population is 13.5%, of which the frequency of
      allergic rhinitis increased from 23% to 38% in the children, and 61.9% in the graduate
      students. Despite intranasal steroid being the current first-line treatment of patients with
      allergic rhinitis, only 60% of patients achieve excellent control. Persistent nasal
      congestion is the major symptom which is difficult to control in these patients. Data are
      limited about efficacy and safety of the additional use of 0.05% intranasal oxymetazoline
      hydrochloride (OXY) for persistent nasal congestion that does not adequately respond to
      recommended doses of intranasal steroid (INS) and oral antihistamine(OAH).

      Objective To determine the efficacy and safety of the additional use of OXY for persistent
      nasal congestion in allergic rhinitis or non-allergic rhinitis patients inadequately
      controlled by combination treatment with INS and OAH.

      Methods The investigators performed a 6-week, randomized, double blind, placebo controlled,
      clinical trial in 50 patients with allergic rhinitis or non-allergic rhinitis whom
      inadequately controlled by combination treatment with INS and oral antihistamine (OAH). After
      an initial screening, qualified individuals were randomized into 2 groups including the
      treatment group and the control group. The treatment group received the INS (2 puffs in each
      nostril twice daily) and OAH (1 tablet once daily) plus OXY (2 puffs in each nostril twice
      daily) The control group received INS (2 puffs in each nostril twice daily) and OAH (1 tablet
      once daily) plus placebo (2 puffs in each nostril twice daily).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All participants will continue medications for 4 weeks, then stop using interventional
      medication and still take INS (2 puffs in each nostril twice daily) and OAH (1 tablet once
      daily) for 2 more weeks. Then, all participants will come for the last visit to see whether
      rebound nasal symptoms occur. Participants will be asked to record nasal symptom diary card,
      and nasal peak inspiratory flow. Rhinoconjunctivitis Quality of life Questionnaire (Rcq) will
      be recorded during visit.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effectiveness of Oxymetazoline in the Treatment of Rhinitis With Persistent Nasal Obstruction</measure>
    <time_frame>6 weeks</time_frame>
    <description>Primary outcome measure is the nasal congestion score measuring by visual analog scale (VAS) ranging from 1-10 (0 = no symptom and 10 = the most severe symptom) compared between treatment group and controlled group.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Numbers of Subjects Who Developed Rhinitis Medicamentosa After Using Oxymetazoline</measure>
    <time_frame>6 weeks</time_frame>
    <description>Rhinitis medicamentosa is the rebound nasal congestion after prolonged use (&gt;7 days) of topical nasal decongestant (eg. oxymetazoline). However, a previous study by Baroody FM et al (J Allergy Clin Immunol 2011;127:927-34) showed that using oxymetazoline together with intranasal steroid for 1 month did not increase rhinitis medicamentosa compared to placebo. So we give rhinitis patients in the treatment group with oxymetazoline and intranasal steroid for 1 month, then stop using oxymetazoline and come back for the last visit 2 weeks later to see which patients develop rebound nasal congestion (rhinitis medicamentosa).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Nasal Obstruction Present Finding</condition>
  <arm_group>
    <arm_group_label>oxymetazoline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.05% oxymetazoline nasal sprays 2 sprays in each nostril twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo nasal spray 2 sprays in each nostril twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxymetazoline</intervention_name>
    <description>0.05% Oxymetazoline nasal sprays were commercially available.</description>
    <arm_group_label>oxymetazoline</arm_group_label>
    <other_name>Iliadin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo nasal spray</intervention_name>
    <description>Placebo nasal spray has made by the local pharmaceutical company in thailand who commercially manufacture and sell 0.05% oxymetazoline nasal spray. The placebo contains the same ingredients as the drug except the active ingredient.</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient 18 years of age or greater

          -  Diagnosis with allergic or nonallergic rhinitis with persistent nasal obstruction

          -  Being treated with intranasal steroid and oral antihistamine

        Exclusion Criteria:

          -  Underlying disease of hypertension

          -  Use oral or nasal decongestant 7 days prior to entering the study

          -  Nasal polyp or significant deviated nasal septum

          -  Respiratory tract infection 14 days prior to entering the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Torpong Thongngarm, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mahidol University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Panitan Pradubpongsa, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Mahidol University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Paraya Assanasen, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Mahidol University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pongsakorn Tantilipikorn, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Mahidol University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Faculty of Medicine Siriraj Hospital, Mahidol University</name>
      <address>
        <city>Bangkok</city>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 14, 2013</study_first_submitted>
  <study_first_submitted_qc>May 1, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 6, 2013</study_first_posted>
  <results_first_submitted>December 9, 2014</results_first_submitted>
  <results_first_submitted_qc>January 3, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 5, 2015</results_first_posted>
  <last_update_submitted>January 3, 2015</last_update_submitted>
  <last_update_submitted_qc>January 3, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 5, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rhinitis</keyword>
  <keyword>Oxymetazoline</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Nasal Obstruction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxymetazoline</mesh_term>
    <mesh_term>Phenylephrine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Eligible patients from medical clinic were instructed to record the severity of nasal congestion 3 days prior to randomization. The severity of nasal congestion was recorded on a 0 to 3 scale (0 = no symptom and 3 = severe symptom). Participants who had nasal congestion score of 1 or greater were recruited for randomization.</recruitment_details>
      <pre_assignment_details>Exclusion if patients with a history suggestive of cardiovascular, hepatic or renal diseases, pregnant or lactating women, taking oral or nasal decongestant within 7 days, treated with immunotherapy, patients with nasal polyp or significant deviated nasal septum and patient with a history of upper respiratory tract infection within 14 days.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Oxymetazoline</title>
          <description>0.05% oxymetazoline nasal sprays 2 sprays in each nostril twice daily
oxymetazoline: 0.05% Oxymetazoline nasal sprays were commercially available.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>placebo nasal spray 2 sprays in each nostril twice daily
Placebo nasal spray: Placebo nasal spray has made by the local pharmaceutical company in thailand who commercially manufacture and sell 0.05% oxymetazoline nasal spray. The placebo contains the same ingredients as the drug except the active ingredient.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline analysis were performed to compared between 2 groups on age, gender results of allergy skin tests and baseline nasal congestion scores.</population>
      <group_list>
        <group group_id="B1">
          <title>Oxymetazoline</title>
          <description>0.05% oxymetazoline nasal sprays 2 sprays in each nostril twice daily
oxymetazoline: 0.05% Oxymetazoline nasal sprays were commercially available.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>placebo nasal spray 2 sprays in each nostril twice daily
Placebo nasal spray: Placebo nasal spray has made by the local pharmaceutical company in thailand who commercially manufacture and sell 0.05% oxymetazoline nasal spray. The placebo contains the same ingredients as the drug except the active ingredient.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
            <count group_id="B2" value="25"/>
            <count group_id="B3" value="50"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Age, gender, allergy skin prick testing for aeroallergens and baseline nasal congestion scores were measured.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Thailand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>nasal congestion scores</title>
          <description>The severity of nasal congestion was recorded on a 0 to 3 scale (0 = no symptom, 1= mild symptom, 2 = moderate symptom and 3 = severe symptom).</description>
          <units>units on a scale</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.73" spread="0.54"/>
                    <measurement group_id="B2" value="1.78" spread="0.64"/>
                    <measurement group_id="B3" value="1.76" spread="0.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Effectiveness of Oxymetazoline in the Treatment of Rhinitis With Persistent Nasal Obstruction</title>
        <description>Primary outcome measure is the nasal congestion score measuring by visual analog scale (VAS) ranging from 1-10 (0 = no symptom and 10 = the most severe symptom) compared between treatment group and controlled group.</description>
        <time_frame>6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oxymetazoline</title>
            <description>0.05% oxymetazoline nasal sprays 2 sprays in each nostril twice daily
oxymetazoline: 0.05% Oxymetazoline nasal sprays were commercially available.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo nasal spray 2 sprays in each nostril twice daily
Placebo nasal spray: Placebo nasal spray has made by the local pharmaceutical company in thailand who commercially manufacture and sell 0.05% oxymetazoline nasal spray. The placebo contains the same ingredients as the drug except the active ingredient.</description>
          </group>
        </group_list>
        <measure>
          <title>Effectiveness of Oxymetazoline in the Treatment of Rhinitis With Persistent Nasal Obstruction</title>
          <description>Primary outcome measure is the nasal congestion score measuring by visual analog scale (VAS) ranging from 1-10 (0 = no symptom and 10 = the most severe symptom) compared between treatment group and controlled group.</description>
          <units>units on a scale</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.38" lower_limit="0.95" upper_limit="1.81"/>
                    <measurement group_id="O2" value="1.67" lower_limit="1.19" upper_limit="2.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Numbers of Subjects Who Developed Rhinitis Medicamentosa After Using Oxymetazoline</title>
        <description>Rhinitis medicamentosa is the rebound nasal congestion after prolonged use (&gt;7 days) of topical nasal decongestant (eg. oxymetazoline). However, a previous study by Baroody FM et al (J Allergy Clin Immunol 2011;127:927-34) showed that using oxymetazoline together with intranasal steroid for 1 month did not increase rhinitis medicamentosa compared to placebo. So we give rhinitis patients in the treatment group with oxymetazoline and intranasal steroid for 1 month, then stop using oxymetazoline and come back for the last visit 2 weeks later to see which patients develop rebound nasal congestion (rhinitis medicamentosa).</description>
        <time_frame>6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oxymetazoline</title>
            <description>0.05% oxymetazoline nasal sprays 2 sprays in each nostril twice daily
oxymetazoline: 0.05% Oxymetazoline nasal sprays were commercially available.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo nasal spray 2 sprays in each nostril twice daily
Placebo nasal spray: Placebo nasal spray has made by the local pharmaceutical company in thailand who commercially manufacture and sell 0.05% oxymetazoline nasal spray. The placebo contains the same ingredients as the drug except the active ingredient.</description>
          </group>
        </group_list>
        <measure>
          <title>The Numbers of Subjects Who Developed Rhinitis Medicamentosa After Using Oxymetazoline</title>
          <description>Rhinitis medicamentosa is the rebound nasal congestion after prolonged use (&gt;7 days) of topical nasal decongestant (eg. oxymetazoline). However, a previous study by Baroody FM et al (J Allergy Clin Immunol 2011;127:927-34) showed that using oxymetazoline together with intranasal steroid for 1 month did not increase rhinitis medicamentosa compared to placebo. So we give rhinitis patients in the treatment group with oxymetazoline and intranasal steroid for 1 month, then stop using oxymetazoline and come back for the last visit 2 weeks later to see which patients develop rebound nasal congestion (rhinitis medicamentosa).</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Oxymetazoline</title>
          <description>0.05% oxymetazoline nasal sprays 2 sprays in each nostril twice daily
oxymetazoline: 0.05% Oxymetazoline nasal sprays were commercially available.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>placebo nasal spray 2 sprays in each nostril twice daily
Placebo nasal spray: Placebo nasal spray has made by the local pharmaceutical company in thailand who commercially manufacture and sell 0.05% oxymetazoline nasal spray. The placebo contains the same ingredients as the drug except the active ingredient.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <description>Difficulty of sleep without other specific symptoms.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Numbness at lips or tongue</sub_title>
                <description>The sense of numbness at lips or tongue without neurological localizing sign.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <description>Headache includes functional headache without localizing signs.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <description>Upper respiratory tract infection including common cold, pharyngitis, etc</description>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="25"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Nasal discomfort</sub_title>
                <description>Nasal discomfort includes nasal irritation and nasal pain.</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="25"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <description>Epistaxis due to local irritation.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Further studies with larger numbers of subjects and longer period of follow-up would probably have led to significant differences between both treatment groups in NPIF, Rcq scores and the possible rebound nasal congestion or other adverse events.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Torpong Thongngarm, M.D.</name_or_title>
      <organization>Faculty of Medicine Siriraj Hospital, Mahidol University</organization>
      <phone>66-2-419-8263</phone>
      <email>torpong.tho@mahidol.ac.th</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

